<< Back to News

System Formulary Update
Nirmatrelvir/ritonavir (Paxlovid)

Situation

Nirmatrelvir/ritonavir (Paxlovid) 300 mg/100 mg and 150 mg/100 mg tablets were approved for addition to the UNC Health System Formulary at the January 2023 System Pharmacy and Therapeutics Committee meeting.

Paxlovid will be RESTRICTED to patients who meet EUA criteria AND were admitted for an indication other than COVID-19 OR initiated Paxlovid prior to admission with the treatment team wanting to finish out the 5-day course.

Background

The following medications were reviewed:

• Nirmatrelvir/ritonavir (Paxlovid) 300 mg/100 mg tablets
• Nirmatrelvir/ritonavir (Paxlovid) 150 mg/100 mg tablets

Assessment/Recommendations

System P&T voted to include the following products on the UNC Health System Medication Formulary:

• Nirmatrelvir/ritonavir (Paxlovid) 300 mg/100 mg tablets
• Nirmatrelvir/ritonavir (Paxlovid) 150 mg/100 mg tablets

Note: Stock of this formulary product may vary at individual entities

Formulary/Epic changes will Go-Live on Tuesday, February 28, 2023.